Viking Therapeutics, Inc.
A clinical-stage biopharmaceutical company in San Diego that develops experimental drugs for metabolic and endocrine disorders, including obesity. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being tested as both a weekly injection and a daily pill for weight loss. Founded in 2012 by Brian Lian, a former Wall Street biotech analyst, the company built its early pipeline by licensing programs from Ligand Pharmaceuticals.
Granted 560.0K · Sold 411.6K
Granted 4.15M · Sold 1.93M
Granted 105.0K
Granted 1.23M · Sold 672.1K
Granted 1.01M · Sold 615.3K
Granted 70.0K
Granted 37.7K
Granted 39.9K · Bought 104.3K · Sold 29.0K
Granted 107.8K · Sold 21.6K
Granted 57.9K · Bought 48.0K · Sold 54.8K
Granted 103.2K · Bought 30.0K · Sold 100.0K
Granted 71.9K · Bought 9.5K · Sold 68.8K
Bought 8.0K
Bought 4.5K
Granted 69.2K · Bought 1.2K · Sold 66.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc10% owner · 5 transactions | — | 5.82Mas of Aug 2020 | 560.0K | — | 411.6K |
| Lian BrianPresident & CEO, Director · 95 transactions | — | 2.60M | 4.15M | — | 1.93M |
| Dinerman MichaelChief Operating Officer · 4 transactions | — | 576.8Kas of May 2015 | 105.0K | — | — |
| Mancini MariannaChief Operating Officer · 73 transactions | — | 409.2K | 1.23M | — | 672.1K |
| Zante GregChief Financial Officer · 80 transactions | — | 189.9K | 1.01M | — | 615.3K |
| Hanley RochelleChief Medical Officer · 4 transactions | — | 160.8Kas of May 2016 | 70.0K | — | — |
| Masamune HirokoChief Development Officer · 2 transactions | — | 141.1Kas of Jan 2019 | 37.7K | — | — |
| Foehr Matthew WDirector · 11 transactions | — | 132.0K | 39.9K | 104.3K | 29.0K |
| Morneau MichaelVP, Finance and Administration · 14 transactions | — | 116.1Kas of Jan 2021 | 107.8K | — | 21.6K |
| Macartney LawsonDirector · 10 transactions | — | 51.1K | 57.9K | 48.0K | 54.8K |
| Rowland Charles A JrDirector · 8 transactions | — | 33.1K | 103.2K | 30.0K | 100.0K |
| Singleton J MatthewDirector · 18 transactions | — | 12.7K | 71.9K | 9.5K | 68.8K |
| Webster Stephen WDirector · 1 transaction | — | 8.0Kas of May 2018 | — | 8.0K | — |
| Aubuchon Neil WilliamChief Commercial Officer · 1 transaction | — | 4.5K | — | 4.5K | — |
| Rouan Sarah KathrynDirector · 8 transactions | — | 4.4K | 69.2K | 1.2K | 66.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over all recorded history: -3.77M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.